The effect of Huoxue Huayu decoction on restenosis after percutaneous coronary intervention in patients with coronary heart disease
A protocol for systematic review and meta-analysis
Yi Hou, MB, Xuhao Li, MB, Xingxin Wang, MB, Tiantian Dong, MB, Jiguo Yang, MB

Abstract
Background: Percutaneous coronary intervention (PCI), as the most common treatment for coronary heart disease (CHD), has the advantages of simple operation, minimal invasion, rapid reconstruction, and vessels opening. The problem, however, is that many patients develop restenosis within 6 months after PCI. In traditional Chinese medicine (TCM), Huoxue Huayu decoction (HXHYD) is widely used to treat cardiovascular diseases, and its important role as a complementary and alternative therapy for the prevention and treatment of post-PCI restenosis in CHD patients has been extensively reported. However, controversy exists among different studies. Therefore, we collected relevant randomized controlled trials for a meta-analysis to assess the efficacy and safety of HXHYD in the prevention of post-PCI restenosis in patients with CHD.

Methods: Randomized controlled trials of HXHYD in the prevention of post-PCI restenosis in patients with CHD will be retrieved from PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wan Fang Database, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, and Clinical Trial Register. The 2 authors will independently conduct the literature search, literature screening, data extraction, and quality assessment. Data analysis will be performed using STATA 14.0.

Results: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication.

Conclusion: This study will provide high-quality, evidence-based medical evidence for the efficacy and safety of HXHYD in the prevention of post-PCI restenosis in patients with CHD.

Ethics and dissemination: Ethical approval is not required for this study. The systematic review will be published in a peer-reviewed journal, presented at conferences, and shared on social media platforms. This review would be disseminated in a peer-reviewed journal or conference presentations.

OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/PNZSM.

Abbreviations: CHD = coronary heart disease, HXHYD = Huoxue Huayu decoction, RCTs = randomized controlled trials.

Keywords: coronary heart disease, coronary restenosis, Huoxue Huayu decoction, meta-analysis, percutaneous coronary intervention, protocol

1. Introduction
Coronary atherosclerotic heart disease refers to a heart disease caused by myocardial ischemia, hypoxia, or necrosis due to lumen stenosis or occlusion caused by atherosclerosis of the coronary arteries, referred to as coronary heart disease (CHD). The current treatment for CHD focuses on drug therapy, coronary artery bypass grafting, and percutaneous coronary intervention (PCI). PCI is the main treatment for CHD. However, post-PCI restenosis remains a challenging clinical problem. Restenosis is defined as a lumen occlusion of more than 50%. This usually occurs within 6 months after PCI, and the mechanism for this is not fully understood.

With the continuous update and development of drug-eluting stents and new anticoagulant drugs, the incidence of restenosis has decreased significantly, but restenosis still occurs in 10% of patients. The conventional drug therapy in Western medicine is not effective in patients with post-PCI restenosis, which makes the search for drugs to prevent post-PCI restenosis an urgent problem.
In China, traditional Chinese medicine (TCM) is widely used for the prevention and treatment of cardiovascular diseases. Clinical studies have found that TCM can reduce the incidence of post-PCI restenosis. CHD falls into the category of blood stasis evidence with blood stasis and phlegm obstruction, Qi deficiency and cold clotting in TCM. Post-PCI restenosis is caused by damage to the arteries and channels based on Qi deficiency, internal stasis of blood and paralysis of the heart channels. Therefore, tonifying Qi and activating blood stasis is the general principle of treatment for patients with post-PCI restenosis.

Huxue Huayu decoction (HXHYD) is composed of Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Paeoniae Alba, and Peach kernel etc, which can reduce myocardial reperfusion injury by activating blood circulation and resolving blood stasis, regulating Qi and relieving pain. In recent years, several studies have shown the importance of HXHYD as a complementary and alternative therapy to prevent post-PCI restenosis in patients with CHD. However, controversy exists among different studies. Therefore, we collected relevant randomized controlled trials (RCTs) for a meta-analysis to assess the efficacy and safety of HXHYD for the prevention of post-PCI restenosis in patients with CHD.

2. Methods

2.1. Study registration

The protocol of the systematic review has been registered on Open Science Framework (registration number: DOI 10.17605/OSF.IO/PNZSM). It was reported by following the guideline of Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocol statement.

2.2. Inclusion criteria for study selection

2.2.1. Type of studies. RCTs of HXHYD for preventing post-PCI restenosis in patients with CHD will be included.

2.2.2. Type of participants. All patients with CHD after PCI were included.

2.2.3. Types of intervention. The control group was given Western medicine alone. The intervention group was treated with HXHYD in combination with Western medicine.

2.2.4. Outcome measurements. Primary outcomes: coronary restenosis was recorded as the primary outcome, defined as stenosis >50% of the diameter.

Secondary outcomes: major adverse cardiac events and the Seattle Angina Questionnaires.

2.3. Exclusion criteria

1. Duplicate publications in the literature.
2. Case series, case reports, reviews, etc.
3. Animal experiments and cellular experiments.

2.4. Data sources and search strategy

This study conducted a literature search in PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wan Fang Database, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, and Clinical Trial Register. We made a final search in January 2022. The search strategy for Pubmed is displayed in Table 1. Similar search strategies will be applied to other electronic databases.

2.5. Data collection and analysis

2.5.1. Study selection. The 2 researchers performed literature screening and data extraction independently. First, the retrieved literature will be imported into the literature management software Endnote for duplicate data removal. After reading the title, abstract and keywords, these 2 researchers will independently select relevant studies. After reading the full text, these 2 researchers will screen the rest of the literature. Any discrepancies between the 2 reviewers will be discussed and resolved by a third researcher. If the required information is missing, the authors will be contacted. The screening flow chart of this study is demonstrated in Figure 1.

2.5.2. Data extraction. The 2 researchers independently extracted data using a pre-determined data extraction form. Contents included general information (title, authors, date of publication, literature source), participants (number of cases, age, sex, duration of disease), interventions (dose of HXHYD, duration and frequency of intervention, duration of follow-up), outcome indicators (coronary restenosis, major adverse cardiac events, and the Seattle Angina Questionnaires) and literature quality evaluation details.
2.5.3. **Dealing with missing data.** If the data of the required study are incomplete or not reported in the study, the researcher will contact the first author or other authors of the study by phone or email. If the required data are not available, we will conduct a descriptive analysis, instead of meta-analysis, and exclude these studies if necessary.

2.6. **Quality assessment**

RCT quality was rated according to the risk of bias tool from the Cochrane Collaboration. The 2 investigators independently and blindly checked the studies. Any discrepancies between the 2 investigators were resolved by consensus.

2.7. **Statistical analysis**

All of the above statistical analyses were performed with Stata 14.0 (StataCorp LLC, college station, TX). Relative risk with 95% confidence interval will be used to measure the curative effect for dichotomous variables, and the standardized mean difference with 95% confidence interval will be used for continuous data. The $I^2$ statistic and Cochran $Q$ test were used to assess homogeneity among the RCTs. If $I^2$ is <50%, a fixed-effects model is applied. If $I^2$ is >50%, a random-effects model is applied. If $I^2$ is >85%, no meta-analyses is performed.

2.8. **Subgroup analysis**

Subgroup analyses were conducted based on dose of HXHYD and sample size.

2.9. **Sensitivity analysis**

In order to test the stability of the meta-analysis results, sensitivity analysis was performed by removing each study in turn to verify the consistency of the results.
2.10. Reporting bias
Funnel plots were used to evaluate publication bias.

2.11. Ethics and dissemination
Since the program does not include the recruitment of patients and the collection of personal information, the approval of the Ethics Committee is not required.

3. Discussion
CHD is the most common cardiovascular disease, primarily due to coronary artery stenosis or obstruction caused by atherosclerosis.[22] PCI is one of the important tools for the treatment of CHD, but the consequent occurrence of restenosis severely affects the efficacy of PCI in CHD patients.[23–25] Although drug-eluting stents can reduce the incidence of restenosis in the short term, the incidence of restenosis remains high in the end. Therefore, it is particularly important to find a safe and effective treatment to prevent post-PCI restenosis in CHD patients. In recent years, a number of studies have demonstrated the efficacy of HXHYD in preventing and treating post-PCI restenosis in patients with CHD. However, the efficacy of different studies is still controversial. In this study, for the first time, a meta-analysis was used to evaluate the efficacy and safety of HXHYD for the prevention and treatment of post-PCI restenosis in patients with CHD. Therefore, this study is expected to provide a reliable basis for the clinical application of HXHYD to prevent post-PCI restenosis in patients with CHD.

Author contributions
Conceptualization: Yi Hou, Jiguo Yang.
Data curation: Yi Hou, Xuhao Li.
Formal analysis: Xuhao Li.
Funding acquisition: Jiguo Yang.
Investigation: Xuhao Li, Tiantian Dong.
Methodology: Xuhao Li, Tiantian Dong.
Project administration: Jiguo Yang.
Resources: Xingxin Wang, Tiantian Dong, Jiguo Yang.
Software: Xingxin Wang, Tiantian Dong.
Supervision: Jiguo Yang.
Validation: Xingxin Wang.
Visualization: Xingxin Wang.
Writing – original draft: Yi Hou, Jiguo Yang.
Writing – review & editing: Yi Hou, Jiguo Yang.

References
[1] Hagstrom E, Norlund F, Stebbins A, et al. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med 2018;283:83–92.
[2] Tian Y, Deng P, Li B, et al. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance. Rev Cardiovas Med 2019;20:27–33.
[3] Jiang H, Zhang H, Yang Y, Yang X. Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China. BMJ Open 2020;10:e039405.
[4] Kurlt A, Eckid D. Procalcitonin is an independent predictor for coronary atherosclerotic burden in patients with stable coronary artery disease. Int J Cardiol 2017;236:61–4.
[5] Liu Z, Xia H, Yang Y, Li J. Risk factors of in-stent restenosis in coronary artery disease patients with CYP2C19. J Pract Med 2016;32:1088–92.
[6] Hee L, Terluk A, Thomas L, et al. Late clinical outcomes for SeQuest please paclitaxel-coated balloons in PCI of instent restenosis and de novo lesions: A single-center, real world registry. Catheter Cardiovasc Interv 2017;89:375–82.
[7] Nunez-Gil JJ, Bautista D, Cerrato E, et al. Incidence, management, and immediate- and long-term outcomes after iatrogenic aortic dissection during diagnostic or interventional coronary procedures. Circulation 2015;131:2114–9.
[8] Zhang KJ, Zheng Q, Zhu PC, et al. Traditional Chinese medicine for coronary heart disease: clinical evidence and possible mechanisms. Front Pharmacol 2019;10:844.
[9] Luo J, Xu H. Outcome measures of Chinese herbal medicine for coronary heart disease: an overview of systematic reviews. Evid Based Complement Alternat Med 2012;2012:927392.
[10] Dai QQ, Shi ZF, Hu JY, et al. Meta-analysis of effect of Qshen Yuqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2021;46:1498–510.
[11] Wu HL, Wang YF, Li JZ, et al. A multicentre randomized clinical trial on efficacy and safety of huxin formula in patients undergoing percutaneous coronary intervention. Evid Based Complement Alternat Med 2014;2014:143064.
[12] Jiang H, Zhang H, Yang Y, Yang X. Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011;17:669–74.
[13] Tao CG, Fu XH, Yuan JQ, et al. Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database System Rev 2015;Cd010237.
[14] Lu XY, Shi DZ, Xu H. Clinical study on effect of xiongshao capsule on restenosis after percutaneous coronary intervention. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006;26:13–7.
[15] Tang Z, Q Q. Effect of Tongmai Huayu decoction on clinical symptoms and coronary restenosis in elderly patients with coronary heart disease after percutaneous coronary intervention. China Med Pharm 2021;16:4.
[16] Wang Y, Chen Y. TCM syndrome differentiation and treatment for post-PCI restenosis. J Pract Trad Chin Intern Med 2019;3.
[17] Liu S. Application of Huoxue Huayu Decoction in patients with restenosis after coronary artery stenting. Med Equip 2020;33:2.
[18] Wang J, Wei C, Pan M, Liu X, Pan Y. Effect of Huoxue Huayu decoction on Wnt/b-catenin signal pathway expression in rats with severe traumatic brain injury. Zhonghua wei zhong bing ji jiu yi xue 2020;32:1101–6.
[19] Zhu L. The effect of Huoxue Huayu Decoction on patients with restenosis after coronary artery stenting. J Emerg Trad Chin Med 2017;26:3.
[20] Li T, Liu B, Wang H, Zhang M, Li D. Effect of Huoxue Huayu Decoction on the expression of cellular inflammatory factors, sICAM-1 and MMP-9 in patients with restenosis after coronary artery stenting. Chin J Integr Med Cardio/Cerebrovasc Dis 2019;17:4.
[21] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed) 2015;350:g7647.
[22] Koenigstein M, Ben-Yehuda O, Smits PC, et al. Outcomes among diabetic patients undergoing percutaneous coronary intervention with contemporary drug-eluting stents: analysis from the BIONICS randomized trial. JACC Cardiovasc Interv 2016;9:1120–32.
[23] Gao S, Shen J, Mukku VK, Wang MJ, Akhtar M, Liu W. Efficacy of drug-eluting balloons for patients with in-stent restenosis: a meta-analysis of 8 randomized controlled trials. Angiology 2016;67:612–21.
[24] Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv 2015;8:382–94.
[25] Gao L, Wang YB, Jing J, Zhang M, Chen YD. Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies. J Geriatr Cardiol 2019;16:448–57.